CA2110979C - Voice suppression of vagal stimulation - Google Patents
Voice suppression of vagal stimulation Download PDFInfo
- Publication number
- CA2110979C CA2110979C CA002110979A CA2110979A CA2110979C CA 2110979 C CA2110979 C CA 2110979C CA 002110979 A CA002110979 A CA 002110979A CA 2110979 A CA2110979 A CA 2110979A CA 2110979 C CA2110979 C CA 2110979C
- Authority
- CA
- Canada
- Prior art keywords
- speech
- patient
- nerve
- sensing
- stimulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36135—Control systems using physiological parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36053—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for vagal stimulation
Abstract
In conjunction with a medical device for stimulating the vagus nerve of a patient to modulate the electrical activity thereof as part of a prescribed therapy, apparatus is provided to selectively suppress the stimulation while the patient is speaking, to avoid undesirable modulation of the voice. The suppression apparatus includes a speech sensor and discriminator, to detect speech by the patient white avoiding false detection attributable to sounds other than speech. The suppression of nerve stimula-tion is ceased after a preset time interval regardless of continued detection of speech, to assure that beneficial therapy is not undu-ly inhibited in favor of mere cosmetic considerations or in the presence of prolonged false defections. In the preferred embodi-ment, the discriminator selectively varies the sensitivity of the suppression apparatus to speech by the patient to enhance its selectivity over sounds attributable to other sources. The apparatus comprises an electrode array (40), an electrical lead (42), a generator (10), and a wand (55).
Description
WO 92/22348 . , PCT/US92/04819 VOICE SUPPRESSION OF VAGAL STIMULATIONv.
Backq~ound of the Invention The present invention relates generally to techniques for stimulation of the vague nerve, and more particularly to methods and apparatus for suppressing or inhibiting stimulation of the vague nerve while the individual undergoing the stimula-tion is speaking.
Neural..stimulating devices (neurostimulators) for generating and applying electrical impulses to the vague nerve -. of an epileptic patient to_modulate the electrical activity of the nerves) as part of .a prescribed therapy are currently undergoing clinical. testing and investfgation.. A side effect of such vagal stimulation in at least some patients is the ' presence of a noticeable modulation of the patient's voice when he or she speaks during actual application of the stimulating signals to the nerve.
It is a principal object of the present invention to provide techniques for avoiding undesirable voice modulation of patients undergoing vagal stimulation therapy.
However, the desire to eliminate an objectionable or annoying modulation of the patient's voice, which is essential-ly a cosmetic consideration, must be balanced against the need to assure that the appropriate therapy will be delivered:
Accordingly, it is another object of the invention to :avoid, to a reasonable extent, undesirable voice modulation of patients undergoing vagal stimulation therapy, while maintain ing a bias in certain circumstances toward ongoing delivery of the therapy as prescribed.
~ummarv of the Invention .. . In essence, in conjunction with a medical device for stimulating the vagus nerve of a patient to modulate the ' electrical activity thereof as part of a prescribed therapy, the present invention provides sensing means to detect the.
patient's speech and to halt or delay the vagal stimulation during at least a part of the time that speech continues to be detected. The result is selective suppression of the stimula-tion while the patient is speaking. The sensing means includes detection and discrimination apparatus, to detect speech by the patient while avoiding false detection attributable to sounds from other sources.
_ _. In a presently preferred embodiment, the suppression of.;.nerve stimulation ceases after a preset time interval regardless of continued detection of speech, to assure that beneficial therapy is not unduly inhibited in favor of mere cosmetic.considerations or. in the presence of prolonged false detections. The discriminator selectively varies the sensitiv-ity of the suppression apparatus to the patients voice while enhancing selectivity over other sounds in the vicinity, for example by changing the value of a threshold level which must be crossed before the suppression of nerve stimulation can occur or continue, and filtering out disturbances.
Although a number of techniques exist by which speech may be detected, such as by sensing myopotentials from muscles involved in speech, or neural potentials, or impedance changes in the tissues involved in speech, for example, the preferred embodiment of the present invention employs a vibration transducer, such as a piezoelectric polymer comrerter, prefera-bly a plastic material commercially available under the trademark Kynar (of Pennwalt Comgany). Alternatively, a piezoelectric crystal. converter may be used as the vibration transducer. The transducer detects vibrations caused by speech-generated sound and converts them to a corresponding electrical signal. It may be located near the vocal tract, or, preferably, for reasons of greater protection and ease of implantation, within the case (housing) of the implantable WO 92/22348 ~ ~ ~ ~ ~ '~ ~ , PGT/US92/04819 microprocessor-based stimulus generator which delivers the programmed therapy to the patient.
~ Although it possesses some clear advantages over other techniques for voice or . speech detection such as those , ~ 5 mentioned above, principally in avoidance of surgical complexi-ties of implantation, a vibration sensor alone is not highly selective of speech-generated sounds or frequencies. However, that shortcoming is readily overcome by appropriate signal enhancement. ~ For example, the system may be designed with programmable or adaptive sensitivities to the signal derived from the speech-generated vibrations. To improve discrimina-tion, selective filtering is performed in the known voice frequency band of from about 300 to about 3,000 Hertz (Hz).
Further noise immunity may be provided by varying the detection thresholds) according to the background noise present.
Therefore, it is another broad object of the present invention to provide improved methods and apparatus for medical therapy through stimulation of the vagus nerve.
A more specific object is to provide a method and . 20 apparatus for vagal neurostimulation which includes selectively suppressing or inhibiting stimulation when the patient is speaking, and avoiding such suppression in the presence of false signals or after prolonged speaking, in favor of delivery of the stimulation therapy.
~:Rrief pescript:on of the Drawings The above and still further objects, features and attendant advantages of the invention will become apparent from a consideration of the following detailed description of the preferred embodiments thereof, taken in conjunction with the accompanying drawings, in which:
WO 92/22348 CA o 2110 9 7 9 2 0 0 0 - o ~ - 2 ~ p~/US92/04819 FIG. 1 is a simplified~block diagram of an exemplary implanta~le neurostimulator to which the principles of the present invention may be applied:
FIGS. 2 is a phantom. view illustrating the relative positions of the implanted neurostimulator, nerve electrode array implanted on the vagus nerve, and associated electrical leads in the patient; and FIG. 3 is a block diagram of an exemplary embodiment of the invention employed in the neurostimulator of FIGS. 1 and 2.
Detailed Description of the Preferred Embodiment a 'l ~p hnrl FIG. 1 is a simplified block diagram of an exemplary stimulus (pulse) generator of a neurostimulator to which the principles of the present invention may be applied. The device is used to treat and/or control epilepsy, for example, by application of appropriate modulating electrical signals to the patient's vagus nerve, as shown in FIG. 2. 'A detailed descrip tion of such a neurostimulator is contained in U.S. patent No.
Backq~ound of the Invention The present invention relates generally to techniques for stimulation of the vague nerve, and more particularly to methods and apparatus for suppressing or inhibiting stimulation of the vague nerve while the individual undergoing the stimula-tion is speaking.
Neural..stimulating devices (neurostimulators) for generating and applying electrical impulses to the vague nerve -. of an epileptic patient to_modulate the electrical activity of the nerves) as part of .a prescribed therapy are currently undergoing clinical. testing and investfgation.. A side effect of such vagal stimulation in at least some patients is the ' presence of a noticeable modulation of the patient's voice when he or she speaks during actual application of the stimulating signals to the nerve.
It is a principal object of the present invention to provide techniques for avoiding undesirable voice modulation of patients undergoing vagal stimulation therapy.
However, the desire to eliminate an objectionable or annoying modulation of the patient's voice, which is essential-ly a cosmetic consideration, must be balanced against the need to assure that the appropriate therapy will be delivered:
Accordingly, it is another object of the invention to :avoid, to a reasonable extent, undesirable voice modulation of patients undergoing vagal stimulation therapy, while maintain ing a bias in certain circumstances toward ongoing delivery of the therapy as prescribed.
~ummarv of the Invention .. . In essence, in conjunction with a medical device for stimulating the vagus nerve of a patient to modulate the ' electrical activity thereof as part of a prescribed therapy, the present invention provides sensing means to detect the.
patient's speech and to halt or delay the vagal stimulation during at least a part of the time that speech continues to be detected. The result is selective suppression of the stimula-tion while the patient is speaking. The sensing means includes detection and discrimination apparatus, to detect speech by the patient while avoiding false detection attributable to sounds from other sources.
_ _. In a presently preferred embodiment, the suppression of.;.nerve stimulation ceases after a preset time interval regardless of continued detection of speech, to assure that beneficial therapy is not unduly inhibited in favor of mere cosmetic.considerations or. in the presence of prolonged false detections. The discriminator selectively varies the sensitiv-ity of the suppression apparatus to the patients voice while enhancing selectivity over other sounds in the vicinity, for example by changing the value of a threshold level which must be crossed before the suppression of nerve stimulation can occur or continue, and filtering out disturbances.
Although a number of techniques exist by which speech may be detected, such as by sensing myopotentials from muscles involved in speech, or neural potentials, or impedance changes in the tissues involved in speech, for example, the preferred embodiment of the present invention employs a vibration transducer, such as a piezoelectric polymer comrerter, prefera-bly a plastic material commercially available under the trademark Kynar (of Pennwalt Comgany). Alternatively, a piezoelectric crystal. converter may be used as the vibration transducer. The transducer detects vibrations caused by speech-generated sound and converts them to a corresponding electrical signal. It may be located near the vocal tract, or, preferably, for reasons of greater protection and ease of implantation, within the case (housing) of the implantable WO 92/22348 ~ ~ ~ ~ ~ '~ ~ , PGT/US92/04819 microprocessor-based stimulus generator which delivers the programmed therapy to the patient.
~ Although it possesses some clear advantages over other techniques for voice or . speech detection such as those , ~ 5 mentioned above, principally in avoidance of surgical complexi-ties of implantation, a vibration sensor alone is not highly selective of speech-generated sounds or frequencies. However, that shortcoming is readily overcome by appropriate signal enhancement. ~ For example, the system may be designed with programmable or adaptive sensitivities to the signal derived from the speech-generated vibrations. To improve discrimina-tion, selective filtering is performed in the known voice frequency band of from about 300 to about 3,000 Hertz (Hz).
Further noise immunity may be provided by varying the detection thresholds) according to the background noise present.
Therefore, it is another broad object of the present invention to provide improved methods and apparatus for medical therapy through stimulation of the vagus nerve.
A more specific object is to provide a method and . 20 apparatus for vagal neurostimulation which includes selectively suppressing or inhibiting stimulation when the patient is speaking, and avoiding such suppression in the presence of false signals or after prolonged speaking, in favor of delivery of the stimulation therapy.
~:Rrief pescript:on of the Drawings The above and still further objects, features and attendant advantages of the invention will become apparent from a consideration of the following detailed description of the preferred embodiments thereof, taken in conjunction with the accompanying drawings, in which:
WO 92/22348 CA o 2110 9 7 9 2 0 0 0 - o ~ - 2 ~ p~/US92/04819 FIG. 1 is a simplified~block diagram of an exemplary implanta~le neurostimulator to which the principles of the present invention may be applied:
FIGS. 2 is a phantom. view illustrating the relative positions of the implanted neurostimulator, nerve electrode array implanted on the vagus nerve, and associated electrical leads in the patient; and FIG. 3 is a block diagram of an exemplary embodiment of the invention employed in the neurostimulator of FIGS. 1 and 2.
Detailed Description of the Preferred Embodiment a 'l ~p hnrl FIG. 1 is a simplified block diagram of an exemplary stimulus (pulse) generator of a neurostimulator to which the principles of the present invention may be applied. The device is used to treat and/or control epilepsy, for example, by application of appropriate modulating electrical signals to the patient's vagus nerve, as shown in FIG. 2. 'A detailed descrip tion of such a neurostimulator is contained in U.S. patent No.
5,154,172, now in the names of Anthony J. Varrichio, et al. assigned to the same assignee as the instant application, with modifica-tions as will be described presently herein. For the moment, a brief description of the basic use, structure and operation of generator 10 of FIG. 1 will suffice.
Typically, pulse generator 10 is implemented to be implanted in the patient (e.g., in a pocket formed by the surgeon just below the skin in the chest as shown in FIG. 2), but the principles of the invention are not restricted to an implantable device and apply equally to a partly or primarily external system. The overall neurostimulator also includes an ~implantable stimulating electrode array 40 and electrical lead system 42 (FIG. 2) for applying the output signal of generator 10 to the selected nerve, such as the vagus nerve. For the implanted device, apparatus would also be employed external to the patient's body, including a computer 53 and wand 55 for telemetry of parameter programming to and monitoring signals from generator 10. The programmed stimulating output pulse 5 sequence of the pulse generator is delivered to the nervets) to modulate the electrical activity thereof.
Generator l0 includes a battery (e. g., a single lithium thionyl chloride cell) 12 connected to a voltage regulator 15 which provides a clean, steady output voltage.
The regulator sugplies power to the various components, including logic and control section 17, which uses a micropro-cessor to control programmable functions of the device includ-ing current (and or voltage), frequency, pulse width, on-time and off-time of the output signal. This allows the output signal to be shaped to obtain the desired modulation of electrical activity of the nerve. Timing signals for~the logic and control functions of the generator are provided by a crystal oscillator 20. A magnetically-actuated reed switch 27 maybe incorporated in the electronics package to provide the capability for.manual activation of the generator (e.g., by the patient, using an external magnet, not shown, placed immediate-ly adjacent to the generator implant site). Built-in antenna enables communication between the implanted pulse generator and the external electronics via the wand 55. Once the system 25 is programmed, it maintains and operates at the programmed =settings until reprogrammed (by the attending physician).
Logic and control section 17 controls an output circuit or section 22 which generates the output signal with the programmed parameters appropriate for treating epilepsy.
The output section and.its programmed output signal are coupled to an electrical connector 30 on the case or housing 35 of generator 10 and to lead assembly 42 connected to the stimu-lating electrode array 40 (FIG. 2). Housing 35 is hermetically sealed and composed of a material such as titanium which is 21.0979 biologically compatible with the fluids and tissue of the.
patient's body.
As shown in FIG. 2, nerve stimulating electrode array 40 is conductively connected. to the distal end of insulated electrically conductive lead assembly 42 which is attached at its proximal end to connector 30 on the generator. Electrode array 40 may be a bipolar stimulating electrode of the type described in U.S. Patent 4,573,481 issued March 4, 1986 to Bullara. The electrode array is surgically implanted on the vague nerve 45 in the patient's neck, and the lead assembly 42 is secured in a manner that allows it to flex with movement of the patient's chest and neck:
It has been found that stimulation of the vague nerve has a side effect of tending to produce an undesirable modula tion of the patient's voice. According to the present inven tion, the neurostimulator includes apparatus for automatically and selectively suppressing or inhibiting the vagal stimulation while the patient is speaking. In the preferred embodiment, this apparatus comprises stimulation suppressor 60 (FIG. ij which is mounted within the housing 35 of the stimulus genera-tor l0. Preferably, a vibration transducer of the suppressor 60 is mounted on the interior surface of the generator housing, mechanically isolated from other internal components to permit free vibration of the transducer so that the suppressor will readily respond to vibrations arising when the patient speaks.
Referring to FIG. 3, the vibration transducer 62 of suppressor 60 is preferably a piezoelectric polymeric material marketed under the name KynarT~, but any suitable material or device may be used which detects vibrations caused by speech-generated sound and converts them to a corresponding electrical signal.
The suppression system processes the speech-derived signal to provide programmable or adaptive sensitivity thereto.
For purposes of initial discrimination between speech signals and other disturbances, the signal is subjected to bandpass W0 92/22348 ~ ; ; PCT/US92/04819 filtering in the voice frequency band ranging from approximate-ly 70 to 3,000 Hz. In the preferred embodiment, the output signal of the vibration transducer 62 is processed through an amplifier/filter 65 having a.bandwidth wider than the speech signal, and is split into two signal paths 67 and 68., The signal in path 67 undergoes rectification in rectifier 70, and is then lowpass filtered via filter 72 in the frequency band of interest (time constant ranging from 0.3 to 3.0 seconds).
The output of filter 72 is applied to one input of a comparator 75.
The signal in path 68 is attenuated in the normal frequency band of speech by a filter 77 having a frequency characteristic' which rejects frequencies in the range from about 300 to about 2,220 Hz. The resulting signal is then rectified in rectifier 80 and lowpass filtered through filter 81 (same as filter 72). The output of filter 81 is combined in summing circuit 84 with a threshold value selected to provide a desired sensitivity to the signal of interest in the presence of ambient or background noise or other interference.
The basic threshold value is programmed into the microprocessor memory in the digital control subsystem 86 of logic and control section 17 of the stimulus generator 10. This digital thresh-old value is converted to an analog value by digital-to-analog (D/A) converter 87 before being combined in sum/difference circuit 84 with the signal processed through path 68. The :combination results in a signal which represents a threshold level exceeding the background noise in the vicinity of the patient and in the system. The cumulative threshold signal is , applied as the second input to comparator 75.
When the first signal (the input from path 67, after processing) exceeds the cumulative threshold (the input from path 68, after processing, together with the threshold value from the microprocessor), it signifies detection of speech by the patient undergoing the neural stimulation. Accordingly, a 8 N ~ ~'Q :~:L~ : . PGT/US92/04819 "detect" signal is outputted from the comparator on line 90 and applied to the microprocessor, via digital control subsystem 86, to suppress stimulation of the vagus nerve by inhibiting the stimulating signal. ..
This basic speech detection system may be modified to avoid if not completely eliminate prolonged false detections, while facilitating rapid detection. Such a modification may be provided, for example, by progressively increasing the sensi-tivity of stimulation suppressor 60. In a preferred technique, the threshold level is initially programmed at a relatively small value so that the detection system is highly sensitive to vibrations indicative of sound, but not necessarily highly selective or capable of discriminating to a great extent between speech-generated sound and sounds deriving from other sources. If the processed first split signal voltage (output of path 67) crosses this threshold, the output of the compara tor triggers suppression of the stimulation signal from the neurostimulator pulse generator. The suppression of stimula tion may be selectively set to be brief, e.g., an interval of five seconds.
To decrease the sensitivity of the suppression system, the threshold is then increased (by prior programming of the microprocessor or by a predetermined added value with each "detect" output of the comparator). If the first split signal voltage exceeds this new threshold value, preferably -:measured within the time interval of the initial suppression, the stimulation signal remains inhibited. Suppression is continued for a period of time which is determined by balancing the patient's need for therapy against the desire to avoid objectionable voice modulation. This period of time is set by the attending physician, by appropriately prograauning the microprocessor in the logic and control section of the stimulus generator. Alternatively, the suppression may be aborted when the first split signal voltage fails to exceed a programmed WO 92/22348 ~ ~ ~ ~ ..~ ~ PGTlUS92/04819 lower threshold level, if that occurs before the end of the, timer interval.
The suppression system may be implemented so that if the comparator fails to produce a "detect" signal output after an initial brief time interval that the first threshold is exceeded and a higher threshold level is established, the higher threshold level is maintained until the periodic testing of the detection subsystem demonstrates that the first split signal level has fallen well below the initial threshold level (i.e., an amount predetermined according to all relevant factors). To further preclude prolonged false detections of patient speech, the suppression system may be programmed to shut down (i.e., to discontinue further suppression) for a predetermined time interval after the physician-programmed period has timed out, or following an aborted detection.
Preferably, also, the sensing portion of the suppres-sion system is implemented to provide a cumulative value representative of the number or extent of the time intervals during which stimulation is suppressed over the course of, for example, a twenty-four hour period. This information may then be utilized to reduce the amount of time of subsequent suppres-sion cycles (i.e., to increase the duty cycle of the basic stimulation) if the summation exceeds a predetermined value for that period. Alternatively, the information may be used to increase the threshold level for speech detection.
When prolonged interruption of stimulation by the suppression system occurs, it tends to indicate that the sounds (vibrations in the system of the preferred embodiment) being detected may not be attributable to patient speech but instead are spurious signals or noise. These may include environmental sounds which are not easily discriminated from speech, such as ' snoring, wheezing or other respiratory problems of the patient.
To avoid prolonged suppression of stimulation in these circum-' stances, the system preferably operates according to an N ~ li, algorithm which treats any prolonged suppression as though it is caused by false detections rather than patient speech. When a predetermined prolonged interval of suppression occurs, the suppression system is disabled. For example, a cumulative total of the intervals of suppression may be maintained by the system to automatically decrease the time interval during which suppression of stimulation is permitted in subsequent inter-vals, and at a predetermined total within a set time period, to prevent suppression altogether. Variations of such schemes, including adjustment of the stimulation or suppression duty cycle, can readily be developed with appropriate algorithms to serve the purpose of biasing the system against.- false detec-tions and prolonged suppression.
It will be observed from the foregoing disclosure that the present invention provides automatic and selective suppression of stimulation of the vague nerve while the patient is speaking, including the capability of automatically aborting the suppression whenever it has continued beyond a prepro grammed time interval. Because the basic function of the neurostimulator system is to modulate the electrical activity of the vague nerve to relieve the incidence and/or length of epileptic seizures (or to alleviate some other disorder being treated), it is preferable to err on the side of stimulation during actual speech by the patient, despite accompanying undesirable voice modulation, than to allow prolonged intervals ;of non-stimulation.
Although a presently preferred embodiment and method of the invention have been described herein, it will be apparent to those skilled in the field of the invention from a consideration of the foregoing disclosure that variations and modifications of the disclosed embodiment and method may be made without departing from the spirit and scope of the invention. For example, the invention is not limited to use with implantable neurostimulators, but may be used effectively h ~,~
where part or substantially all of the neural stimulating apparat>~s is located external to the patient's body. Further-more, the invention is not limited to the application of vagal stimulation for treatment of.epileptic patients. Methods and apparatus for treating other disorders by vagal stimulation are described in U.S. patents Nos. 5,188,104, 5,269,303, 5,215,086, 5,299,569, and 5,335,657. It is therefore intended that the invention shall be limited only to the extent required by the appended claims and the rules and principles of applicable law.
Typically, pulse generator 10 is implemented to be implanted in the patient (e.g., in a pocket formed by the surgeon just below the skin in the chest as shown in FIG. 2), but the principles of the invention are not restricted to an implantable device and apply equally to a partly or primarily external system. The overall neurostimulator also includes an ~implantable stimulating electrode array 40 and electrical lead system 42 (FIG. 2) for applying the output signal of generator 10 to the selected nerve, such as the vagus nerve. For the implanted device, apparatus would also be employed external to the patient's body, including a computer 53 and wand 55 for telemetry of parameter programming to and monitoring signals from generator 10. The programmed stimulating output pulse 5 sequence of the pulse generator is delivered to the nervets) to modulate the electrical activity thereof.
Generator l0 includes a battery (e. g., a single lithium thionyl chloride cell) 12 connected to a voltage regulator 15 which provides a clean, steady output voltage.
The regulator sugplies power to the various components, including logic and control section 17, which uses a micropro-cessor to control programmable functions of the device includ-ing current (and or voltage), frequency, pulse width, on-time and off-time of the output signal. This allows the output signal to be shaped to obtain the desired modulation of electrical activity of the nerve. Timing signals for~the logic and control functions of the generator are provided by a crystal oscillator 20. A magnetically-actuated reed switch 27 maybe incorporated in the electronics package to provide the capability for.manual activation of the generator (e.g., by the patient, using an external magnet, not shown, placed immediate-ly adjacent to the generator implant site). Built-in antenna enables communication between the implanted pulse generator and the external electronics via the wand 55. Once the system 25 is programmed, it maintains and operates at the programmed =settings until reprogrammed (by the attending physician).
Logic and control section 17 controls an output circuit or section 22 which generates the output signal with the programmed parameters appropriate for treating epilepsy.
The output section and.its programmed output signal are coupled to an electrical connector 30 on the case or housing 35 of generator 10 and to lead assembly 42 connected to the stimu-lating electrode array 40 (FIG. 2). Housing 35 is hermetically sealed and composed of a material such as titanium which is 21.0979 biologically compatible with the fluids and tissue of the.
patient's body.
As shown in FIG. 2, nerve stimulating electrode array 40 is conductively connected. to the distal end of insulated electrically conductive lead assembly 42 which is attached at its proximal end to connector 30 on the generator. Electrode array 40 may be a bipolar stimulating electrode of the type described in U.S. Patent 4,573,481 issued March 4, 1986 to Bullara. The electrode array is surgically implanted on the vague nerve 45 in the patient's neck, and the lead assembly 42 is secured in a manner that allows it to flex with movement of the patient's chest and neck:
It has been found that stimulation of the vague nerve has a side effect of tending to produce an undesirable modula tion of the patient's voice. According to the present inven tion, the neurostimulator includes apparatus for automatically and selectively suppressing or inhibiting the vagal stimulation while the patient is speaking. In the preferred embodiment, this apparatus comprises stimulation suppressor 60 (FIG. ij which is mounted within the housing 35 of the stimulus genera-tor l0. Preferably, a vibration transducer of the suppressor 60 is mounted on the interior surface of the generator housing, mechanically isolated from other internal components to permit free vibration of the transducer so that the suppressor will readily respond to vibrations arising when the patient speaks.
Referring to FIG. 3, the vibration transducer 62 of suppressor 60 is preferably a piezoelectric polymeric material marketed under the name KynarT~, but any suitable material or device may be used which detects vibrations caused by speech-generated sound and converts them to a corresponding electrical signal.
The suppression system processes the speech-derived signal to provide programmable or adaptive sensitivity thereto.
For purposes of initial discrimination between speech signals and other disturbances, the signal is subjected to bandpass W0 92/22348 ~ ; ; PCT/US92/04819 filtering in the voice frequency band ranging from approximate-ly 70 to 3,000 Hz. In the preferred embodiment, the output signal of the vibration transducer 62 is processed through an amplifier/filter 65 having a.bandwidth wider than the speech signal, and is split into two signal paths 67 and 68., The signal in path 67 undergoes rectification in rectifier 70, and is then lowpass filtered via filter 72 in the frequency band of interest (time constant ranging from 0.3 to 3.0 seconds).
The output of filter 72 is applied to one input of a comparator 75.
The signal in path 68 is attenuated in the normal frequency band of speech by a filter 77 having a frequency characteristic' which rejects frequencies in the range from about 300 to about 2,220 Hz. The resulting signal is then rectified in rectifier 80 and lowpass filtered through filter 81 (same as filter 72). The output of filter 81 is combined in summing circuit 84 with a threshold value selected to provide a desired sensitivity to the signal of interest in the presence of ambient or background noise or other interference.
The basic threshold value is programmed into the microprocessor memory in the digital control subsystem 86 of logic and control section 17 of the stimulus generator 10. This digital thresh-old value is converted to an analog value by digital-to-analog (D/A) converter 87 before being combined in sum/difference circuit 84 with the signal processed through path 68. The :combination results in a signal which represents a threshold level exceeding the background noise in the vicinity of the patient and in the system. The cumulative threshold signal is , applied as the second input to comparator 75.
When the first signal (the input from path 67, after processing) exceeds the cumulative threshold (the input from path 68, after processing, together with the threshold value from the microprocessor), it signifies detection of speech by the patient undergoing the neural stimulation. Accordingly, a 8 N ~ ~'Q :~:L~ : . PGT/US92/04819 "detect" signal is outputted from the comparator on line 90 and applied to the microprocessor, via digital control subsystem 86, to suppress stimulation of the vagus nerve by inhibiting the stimulating signal. ..
This basic speech detection system may be modified to avoid if not completely eliminate prolonged false detections, while facilitating rapid detection. Such a modification may be provided, for example, by progressively increasing the sensi-tivity of stimulation suppressor 60. In a preferred technique, the threshold level is initially programmed at a relatively small value so that the detection system is highly sensitive to vibrations indicative of sound, but not necessarily highly selective or capable of discriminating to a great extent between speech-generated sound and sounds deriving from other sources. If the processed first split signal voltage (output of path 67) crosses this threshold, the output of the compara tor triggers suppression of the stimulation signal from the neurostimulator pulse generator. The suppression of stimula tion may be selectively set to be brief, e.g., an interval of five seconds.
To decrease the sensitivity of the suppression system, the threshold is then increased (by prior programming of the microprocessor or by a predetermined added value with each "detect" output of the comparator). If the first split signal voltage exceeds this new threshold value, preferably -:measured within the time interval of the initial suppression, the stimulation signal remains inhibited. Suppression is continued for a period of time which is determined by balancing the patient's need for therapy against the desire to avoid objectionable voice modulation. This period of time is set by the attending physician, by appropriately prograauning the microprocessor in the logic and control section of the stimulus generator. Alternatively, the suppression may be aborted when the first split signal voltage fails to exceed a programmed WO 92/22348 ~ ~ ~ ~ ..~ ~ PGTlUS92/04819 lower threshold level, if that occurs before the end of the, timer interval.
The suppression system may be implemented so that if the comparator fails to produce a "detect" signal output after an initial brief time interval that the first threshold is exceeded and a higher threshold level is established, the higher threshold level is maintained until the periodic testing of the detection subsystem demonstrates that the first split signal level has fallen well below the initial threshold level (i.e., an amount predetermined according to all relevant factors). To further preclude prolonged false detections of patient speech, the suppression system may be programmed to shut down (i.e., to discontinue further suppression) for a predetermined time interval after the physician-programmed period has timed out, or following an aborted detection.
Preferably, also, the sensing portion of the suppres-sion system is implemented to provide a cumulative value representative of the number or extent of the time intervals during which stimulation is suppressed over the course of, for example, a twenty-four hour period. This information may then be utilized to reduce the amount of time of subsequent suppres-sion cycles (i.e., to increase the duty cycle of the basic stimulation) if the summation exceeds a predetermined value for that period. Alternatively, the information may be used to increase the threshold level for speech detection.
When prolonged interruption of stimulation by the suppression system occurs, it tends to indicate that the sounds (vibrations in the system of the preferred embodiment) being detected may not be attributable to patient speech but instead are spurious signals or noise. These may include environmental sounds which are not easily discriminated from speech, such as ' snoring, wheezing or other respiratory problems of the patient.
To avoid prolonged suppression of stimulation in these circum-' stances, the system preferably operates according to an N ~ li, algorithm which treats any prolonged suppression as though it is caused by false detections rather than patient speech. When a predetermined prolonged interval of suppression occurs, the suppression system is disabled. For example, a cumulative total of the intervals of suppression may be maintained by the system to automatically decrease the time interval during which suppression of stimulation is permitted in subsequent inter-vals, and at a predetermined total within a set time period, to prevent suppression altogether. Variations of such schemes, including adjustment of the stimulation or suppression duty cycle, can readily be developed with appropriate algorithms to serve the purpose of biasing the system against.- false detec-tions and prolonged suppression.
It will be observed from the foregoing disclosure that the present invention provides automatic and selective suppression of stimulation of the vague nerve while the patient is speaking, including the capability of automatically aborting the suppression whenever it has continued beyond a prepro grammed time interval. Because the basic function of the neurostimulator system is to modulate the electrical activity of the vague nerve to relieve the incidence and/or length of epileptic seizures (or to alleviate some other disorder being treated), it is preferable to err on the side of stimulation during actual speech by the patient, despite accompanying undesirable voice modulation, than to allow prolonged intervals ;of non-stimulation.
Although a presently preferred embodiment and method of the invention have been described herein, it will be apparent to those skilled in the field of the invention from a consideration of the foregoing disclosure that variations and modifications of the disclosed embodiment and method may be made without departing from the spirit and scope of the invention. For example, the invention is not limited to use with implantable neurostimulators, but may be used effectively h ~,~
where part or substantially all of the neural stimulating apparat>~s is located external to the patient's body. Further-more, the invention is not limited to the application of vagal stimulation for treatment of.epileptic patients. Methods and apparatus for treating other disorders by vagal stimulation are described in U.S. patents Nos. 5,188,104, 5,269,303, 5,215,086, 5,299,569, and 5,335,657. It is therefore intended that the invention shall be limited only to the extent required by the appended claims and the rules and principles of applicable law.
Claims (20)
1. A medical device for stimulating the vague nerve of a patient to modulate the electrical activity thereof as part of a prescribed therapy, comprising:
signal generating means for generating a predeter-mined signal to stimulate the vague nerve, and sensing means responsive to speech by the patient for automatically inhibiting said signal from stimulating the nerve.
signal generating means for generating a predeter-mined signal to stimulate the vague nerve, and sensing means responsive to speech by the patient for automatically inhibiting said signal from stimulating the nerve.
2. The invention of claim 1, wherein said sensing means includes means for detecting speech by the patient.
3. The invention of claim 2, wherein said sensing means further includes means for removing the inhibition after a preset time interval regardless of continued detection of speech by the speech detecting means.
4. The invention of claim 2, wherein said sensing means further includes means for discriminating speech by the patient from other sounds to avoid false detection of speech.
5. The invention of claim 1, wherein said sensing means includes means for removing the inhibition after a preset time interval regardless of continued detection of speech by the speech detecting means.
6. The invention of claim 2, wherein said sensing means further includes means for varying the sensitivity of the speech detecting means to speech by the patient, to reduce the likelihood of false detection of speech.
7. The invention of claim 6, wherein said sensing means further includes means for removing the inhibition after a preset time interval regardless of continued detection of speech by the speech detecting means.
8. The invention of claim 4, wherein the speech detecting means includes a vibration sensor.
9. The invention of claim 8, wherein the vibration sensor includes transducer means for converting detected vibrations to an electrical signal, and the speech discriminating means includes bandpass filter means for processing the electrical signal derived from the detected vibrations while substantially rejecting signal frequencies outside the voice frequency band.
10. The invention of claim 6, wherein the sensitivity varying means includes means for progressively decreasing the sensitivity of the speech detect-ing means to speech-generated phenomena, to discriminate against similar phenomena generated by sources other than speech.
11. The invention of claim 1, wherein the sensing means includes means for summing the time intervals of inhibi-tion of the signal generated by said signal generating means during a predetermined period, and means for reducing the time intervals of subsequent inhibitions when the sum of the time intervals of inhibition during said predetermined period exceeds a preset value.
12. The invention of claim 6, wherein the sensing means further includes means for setting a threshold value of the speech detecting means representing a predetermined sensitivity to patient speech, and the sensitivity varying means includes means for progressively increasing the threshold value of the speech detecting means to speech-generated phenomena, with increasing intervals of inhibition.
13. In conjunction with a medical device for stimulating the vague nerve of a patient to modulate the electrical activity of the nerve as part of a prescribed therapy, the improvement comprising:
sensing means responsive to speaking by the patient for automatically suppressing the nerve stimulation.
sensing means responsive to speaking by the patient for automatically suppressing the nerve stimulation.
14. The improvement of claim 13, wherein said sensing means includes means for restoring the capability of the device to further stimulate the vague nerve after a preset time interval regardless of continued speaking by the patient.
15. The improvement of claim 14, wherein said sensing means further includes means for distinguishing speaking by the patient from other phenomena to avoid false responses.
16. The improvement of claim l3, wherein said sensing means includes means for disabling the suppression despite continued speech by the patient.
17. The improvement of claim 13, wherein said sensing means includes means for varying the sensitivity of the device to speech by the patient, after a predetermined time interval in which stimulation is suppressed.
18. A method of avoiding undesirable modulation of the voice of a patient as a consequence of stimulation of the patient's vagus nerve by a medical device to modulate the electrical activity of the nerve as part of a prescribed therapy, said method comprising:
sensing speech by the patient, and responding to said sensing of speech by automatically suppressing the nerve stimulation.
sensing speech by the patient, and responding to said sensing of speech by automatically suppressing the nerve stimulation.
19. The method of claim 18, further including restoring the availability of stimulation after a preset time interval regardless of continued sensing of speech by the patient.
20. The method of claim 18, further including distinguishing speech by the patient from other sounds to avoid suppression of stimulation in response to false detection of speech.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US715,428 | 1991-06-14 | ||
| US07/715,428 US5205285A (en) | 1991-06-14 | 1991-06-14 | Voice suppression of vagal stimulation |
| PCT/US1992/004819 WO1992022348A1 (en) | 1991-06-14 | 1992-06-12 | Voice suppression of vagal stimulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2110979A1 CA2110979A1 (en) | 1992-12-23 |
| CA2110979C true CA2110979C (en) | 2002-01-22 |
Family
ID=24874012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002110979A Expired - Fee Related CA2110979C (en) | 1991-06-14 | 1992-06-12 | Voice suppression of vagal stimulation |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5205285A (en) |
| EP (1) | EP0588957B1 (en) |
| JP (1) | JP3414396B2 (en) |
| AU (1) | AU663719B2 (en) |
| CA (1) | CA2110979C (en) |
| DE (1) | DE69231468T2 (en) |
| WO (1) | WO1992022348A1 (en) |
Families Citing this family (246)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6944501B1 (en) * | 2000-04-05 | 2005-09-13 | Neurospace, Inc. | Neurostimulator involving stimulation strategies and process for using it |
| US20020169485A1 (en) | 1995-10-16 | 2002-11-14 | Neuropace, Inc. | Differential neurostimulation therapy driven by physiological context |
| US6449507B1 (en) * | 1996-04-30 | 2002-09-10 | Medtronic, Inc. | Method and system for nerve stimulation prior to and during a medical procedure |
| US6628987B1 (en) * | 2000-09-26 | 2003-09-30 | Medtronic, Inc. | Method and system for sensing cardiac contractions during vagal stimulation-induced cardiopalegia |
| US6904318B2 (en) * | 2000-09-26 | 2005-06-07 | Medtronic, Inc. | Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure |
| US7225019B2 (en) | 1996-04-30 | 2007-05-29 | Medtronic, Inc. | Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure |
| US7269457B2 (en) * | 1996-04-30 | 2007-09-11 | Medtronic, Inc. | Method and system for vagal nerve stimulation with multi-site cardiac pacing |
| US8036741B2 (en) * | 1996-04-30 | 2011-10-11 | Medtronic, Inc. | Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| US7853329B2 (en) * | 1998-08-05 | 2010-12-14 | Neurovista Corporation | Monitoring efficacy of neural modulation therapy |
| US7242984B2 (en) | 1998-08-05 | 2007-07-10 | Neurovista Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
| US7231254B2 (en) | 1998-08-05 | 2007-06-12 | Bioneuronics Corporation | Closed-loop feedback-driven neuromodulation |
| US7747325B2 (en) | 1998-08-05 | 2010-06-29 | Neurovista Corporation | Systems and methods for monitoring a patient's neurological disease state |
| US6366813B1 (en) | 1998-08-05 | 2002-04-02 | Dilorenzo Daniel J. | Apparatus and method for closed-loop intracranical stimulation for optimal control of neurological disease |
| US8762065B2 (en) | 1998-08-05 | 2014-06-24 | Cyberonics, Inc. | Closed-loop feedback-driven neuromodulation |
| US7277758B2 (en) * | 1998-08-05 | 2007-10-02 | Neurovista Corporation | Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder |
| US7209787B2 (en) * | 1998-08-05 | 2007-04-24 | Bioneuronics Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
| US9042988B2 (en) | 1998-08-05 | 2015-05-26 | Cyberonics, Inc. | Closed-loop vagus nerve stimulation |
| US9415222B2 (en) * | 1998-08-05 | 2016-08-16 | Cyberonics, Inc. | Monitoring an epilepsy disease state with a supervisory module |
| US7403820B2 (en) * | 1998-08-05 | 2008-07-22 | Neurovista Corporation | Closed-loop feedback-driven neuromodulation |
| US9375573B2 (en) | 1998-08-05 | 2016-06-28 | Cyberonics, Inc. | Systems and methods for monitoring a patient's neurological disease state |
| US7324851B1 (en) | 1998-08-05 | 2008-01-29 | Neurovista Corporation | Closed-loop feedback-driven neuromodulation |
| JP2003503119A (en) * | 1999-06-25 | 2003-01-28 | エモリ ユニバーシティ | Vagal nerve stimulation device and method |
| US6453201B1 (en) | 1999-10-20 | 2002-09-17 | Cardiac Pacemakers, Inc. | Implantable medical device with voice responding and recording capacity |
| US6473639B1 (en) | 2000-03-02 | 2002-10-29 | Neuropace, Inc. | Neurological event detection procedure using processed display channel based algorithms and devices incorporating these procedures |
| US6466822B1 (en) | 2000-04-05 | 2002-10-15 | Neuropace, Inc. | Multimodal neurostimulator and process of using it |
| US7146209B2 (en) * | 2000-05-08 | 2006-12-05 | Brainsgate, Ltd. | Stimulation for treating eye pathologies |
| US7117033B2 (en) * | 2000-05-08 | 2006-10-03 | Brainsgate, Ltd. | Stimulation for acute conditions |
| WO2001085094A2 (en) * | 2000-05-08 | 2001-11-15 | Brainsgate Ltd. | Method and apparatus for stimulating the sphenopalatine ganglion to modify properties of the bbb and cerebral blood flow |
| US7640062B2 (en) | 2000-05-08 | 2009-12-29 | Brainsgate Ltd. | Methods and systems for management of alzheimer's disease |
| US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| US8019091B2 (en) | 2000-07-19 | 2011-09-13 | Aliphcom, Inc. | Voice activity detector (VAD) -based multiple-microphone acoustic noise suppression |
| US20030179888A1 (en) * | 2002-03-05 | 2003-09-25 | Burnett Gregory C. | Voice activity detection (VAD) devices and methods for use with noise suppression systems |
| US6487446B1 (en) * | 2000-09-26 | 2002-11-26 | Medtronic, Inc. | Method and system for spinal cord stimulation prior to and during a medical procedure |
| US6529774B1 (en) | 2000-11-09 | 2003-03-04 | Neuropace, Inc. | Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation |
| US6907295B2 (en) * | 2001-08-31 | 2005-06-14 | Biocontrol Medical Ltd. | Electrode assembly for nerve control |
| US6892098B2 (en) | 2001-04-26 | 2005-05-10 | Biocontrol Medical Ltd. | Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders |
| US6684105B2 (en) | 2001-08-31 | 2004-01-27 | Biocontrol Medical, Ltd. | Treatment of disorders by unidirectional nerve stimulation |
| US7974693B2 (en) | 2001-08-31 | 2011-07-05 | Bio Control Medical (B.C.M.) Ltd. | Techniques for applying, configuring, and coordinating nerve fiber stimulation |
| US7734355B2 (en) | 2001-08-31 | 2010-06-08 | Bio Control Medical (B.C.M.) Ltd. | Treatment of disorders by unidirectional nerve stimulation |
| US7778711B2 (en) * | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Reduction of heart rate variability by parasympathetic stimulation |
| US7778703B2 (en) * | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Selective nerve fiber stimulation for treating heart conditions |
| US7885709B2 (en) * | 2001-08-31 | 2011-02-08 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation for treating disorders |
| US8571653B2 (en) * | 2001-08-31 | 2013-10-29 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
| US7904176B2 (en) | 2006-09-07 | 2011-03-08 | Bio Control Medical (B.C.M.) Ltd. | Techniques for reducing pain associated with nerve stimulation |
| US20040048795A1 (en) * | 2002-02-26 | 2004-03-11 | North Shore-Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
| US20090259279A1 (en) * | 2002-03-22 | 2009-10-15 | Dobak Iii John D | Splanchnic nerve stimulation for treatment of obesity |
| US7689276B2 (en) * | 2002-09-13 | 2010-03-30 | Leptos Biomedical, Inc. | Dynamic nerve stimulation for treatment of disorders |
| US7702386B2 (en) * | 2002-03-22 | 2010-04-20 | Leptos Biomedical, Inc. | Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes |
| US7689277B2 (en) * | 2002-03-22 | 2010-03-30 | Leptos Biomedical, Inc. | Neural stimulation for treatment of metabolic syndrome and type 2 diabetes |
| US7236822B2 (en) * | 2002-03-22 | 2007-06-26 | Leptos Biomedical, Inc. | Wireless electric modulation of sympathetic nervous system |
| US7937145B2 (en) * | 2002-03-22 | 2011-05-03 | Advanced Neuromodulation Systems, Inc. | Dynamic nerve stimulation employing frequency modulation |
| US7239912B2 (en) * | 2002-03-22 | 2007-07-03 | Leptos Biomedical, Inc. | Electric modulation of sympathetic nervous system |
| US7551964B2 (en) * | 2002-03-22 | 2009-06-23 | Leptos Biomedical, Inc. | Splanchnic nerve stimulation for treatment of obesity |
| IL164828A0 (en) * | 2002-04-25 | 2005-12-18 | Brainsgate Ltd | Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head |
| US7684859B2 (en) * | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
| US7636597B2 (en) * | 2002-11-14 | 2009-12-22 | Brainsgate, Ltd. | Surgical tools and techniques for stimulation |
| US7561922B2 (en) * | 2004-12-22 | 2009-07-14 | Biocontrol Medical Ltd. | Construction of electrode assembly for nerve control |
| US7321793B2 (en) | 2003-06-13 | 2008-01-22 | Biocontrol Medical Ltd. | Vagal stimulation for atrial fibrillation therapy |
| US7844346B2 (en) * | 2002-05-23 | 2010-11-30 | Biocontrol Medical Ltd. | Electrode assembly for nerve control |
| US8204591B2 (en) * | 2002-05-23 | 2012-06-19 | Bio Control Medical (B.C.M.) Ltd. | Techniques for prevention of atrial fibrillation |
| US7561919B2 (en) * | 2002-11-14 | 2009-07-14 | Brainsgate Ltd. | SPG stimulation via the greater palatine canal |
| US7627384B2 (en) | 2004-11-15 | 2009-12-01 | Bio Control Medical (B.C.M.) Ltd. | Techniques for nerve stimulation |
| US8880192B2 (en) | 2012-04-02 | 2014-11-04 | Bio Control Medical (B.C.M.) Ltd. | Electrode cuffs |
| US9066186B2 (en) | 2003-01-30 | 2015-06-23 | Aliphcom | Light-based detection for acoustic applications |
| US9099094B2 (en) | 2003-03-27 | 2015-08-04 | Aliphcom | Microphone array with rear venting |
| US8060197B2 (en) * | 2003-05-23 | 2011-11-15 | Bio Control Medical (B.C.M.) Ltd. | Parasympathetic stimulation for termination of non-sinus atrial tachycardia |
| EP1648560A4 (en) | 2003-06-13 | 2015-10-28 | Biocontrol Medical Ltd | Vagal stimulation for anti-embolic therapy |
| WO2004110549A2 (en) * | 2003-06-13 | 2004-12-23 | Biocontrol Medical Ltd. | Applications of vagal stimulation |
| US9050469B1 (en) | 2003-11-26 | 2015-06-09 | Flint Hills Scientific, Llc | Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals |
| US8010189B2 (en) * | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
| US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
| US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| JP2007530586A (en) * | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | Nervous hemostasis |
| US7551599B2 (en) * | 2004-03-29 | 2009-06-23 | Corrigent Systems Ltd. | Layer-3 network routing with RPR layer-2 visibility |
| EP1759536B1 (en) * | 2004-06-01 | 2011-05-18 | Kwalata Trading Limited | In vitro techniques for use with stem cells |
| WO2006021957A2 (en) * | 2004-08-23 | 2006-03-02 | Brainsgate Ltd. | Concurrent bilateral spg modulation |
| US7623924B2 (en) * | 2004-08-31 | 2009-11-24 | Leptos Biomedical, Inc. | Devices and methods for gynecologic hormone modulation in mammals |
| US7974223B2 (en) * | 2004-11-19 | 2011-07-05 | Corrigent Systems Ltd. | Virtual private LAN service over ring networks |
| US20060110374A1 (en) * | 2004-11-24 | 2006-05-25 | Dudy Czeiger | Method to accelerate stem cell recruitment and homing |
| US7366571B2 (en) * | 2004-12-10 | 2008-04-29 | Cyberonics, Inc. | Neurostimulator with activation based on changes in body temperature |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| CN101124012B (en) | 2004-12-27 | 2012-09-05 | 范因斯坦医学研究院 | Device for treating inflammatory disorders by electrical vagus nerve stimulation |
| US8609082B2 (en) | 2005-01-25 | 2013-12-17 | Bio Control Medical Ltd. | Administering bone marrow progenitor cells or myoblasts followed by application of an electrical current for cardiac repair, increasing blood supply or enhancing angiogenesis |
| US8600521B2 (en) * | 2005-01-27 | 2013-12-03 | Cyberonics, Inc. | Implantable medical device having multiple electrode/sensor capability and stimulation based on sensed intrinsic activity |
| US7561918B2 (en) | 2005-01-28 | 2009-07-14 | Cyberonics, Inc. | Autocapture in a neurostimulator |
| US9314633B2 (en) | 2008-01-25 | 2016-04-19 | Cyberonics, Inc. | Contingent cardio-protection for epilepsy patients |
| US8565867B2 (en) * | 2005-01-28 | 2013-10-22 | Cyberonics, Inc. | Changeable electrode polarity stimulation by an implantable medical device |
| US8260426B2 (en) * | 2008-01-25 | 2012-09-04 | Cyberonics, Inc. | Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device |
| US7454245B2 (en) | 2005-01-28 | 2008-11-18 | Cyberonics, Inc. | Trained and adaptive response in a neurostimulator |
| US8700163B2 (en) | 2005-03-04 | 2014-04-15 | Cyberonics, Inc. | Cranial nerve stimulation for treatment of substance addiction |
| US7974202B2 (en) | 2005-05-06 | 2011-07-05 | Corrigent Systems, Ltd. | Tunnel provisioning with link aggregation |
| US7840280B2 (en) | 2005-07-27 | 2010-11-23 | Cyberonics, Inc. | Cranial nerve stimulation to treat a vocal cord disorder |
| US7856273B2 (en) | 2005-07-28 | 2010-12-21 | Cyberonics, Inc. | Autonomic nerve stimulation to treat a gastrointestinal disorder |
| US7620455B2 (en) | 2005-10-25 | 2009-11-17 | Cyberonics, Inc. | Cranial nerve stimulation to treat eating disorders |
| US8428731B2 (en) | 2005-10-27 | 2013-04-23 | Cyberonics, Inc. | Sequenced therapy protocols for an implantable medical device |
| US7957796B2 (en) | 2005-10-28 | 2011-06-07 | Cyberonics, Inc. | Using physiological sensor data with an implantable medical device |
| US8694118B2 (en) | 2005-10-28 | 2014-04-08 | Cyberonics, Inc. | Variable output ramping for an implantable medical device |
| US8868172B2 (en) | 2005-12-28 | 2014-10-21 | Cyberonics, Inc. | Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders |
| US8725243B2 (en) | 2005-12-28 | 2014-05-13 | Cyberonics, Inc. | Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
| US7983150B2 (en) * | 2006-01-18 | 2011-07-19 | Corrigent Systems Ltd. | VPLS failure protection in ring networks |
| US7996079B2 (en) * | 2006-01-24 | 2011-08-09 | Cyberonics, Inc. | Input response override for an implantable medical device |
| US20070173890A1 (en) * | 2006-01-24 | 2007-07-26 | Cyberonics, Inc. | Stimulation mode adjustment for an implantable medical device |
| US7974697B2 (en) * | 2006-01-26 | 2011-07-05 | Cyberonics, Inc. | Medical imaging feedback for an implantable medical device |
| US7657310B2 (en) | 2006-01-26 | 2010-02-02 | Cyberonics, Inc. | Treatment of reproductive endocrine disorders by vagus nerve stimulation |
| US7801601B2 (en) * | 2006-01-27 | 2010-09-21 | Cyberonics, Inc. | Controlling neuromodulation using stimulus modalities |
| US7808931B2 (en) * | 2006-03-02 | 2010-10-05 | Corrigent Systems Ltd. | High capacity ring communication network |
| TW200734462A (en) | 2006-03-08 | 2007-09-16 | In Motion Invest Ltd | Regulating stem cells |
| EP2026874B1 (en) | 2006-03-29 | 2015-05-20 | Dignity Health | Vagus nerve stimulation system |
| US7545740B2 (en) * | 2006-04-07 | 2009-06-09 | Corrigent Systems Ltd. | Two-way link aggregation |
| US8180462B2 (en) * | 2006-04-18 | 2012-05-15 | Cyberonics, Inc. | Heat dissipation for a lead assembly |
| US7869885B2 (en) | 2006-04-28 | 2011-01-11 | Cyberonics, Inc | Threshold optimization for tissue stimulation therapy |
| US7962220B2 (en) * | 2006-04-28 | 2011-06-14 | Cyberonics, Inc. | Compensation reduction in tissue stimulation therapy |
| US7593400B2 (en) * | 2006-05-19 | 2009-09-22 | Corrigent Systems Ltd. | MAC address learning in a distributed bridge |
| US8295926B2 (en) | 2006-06-02 | 2012-10-23 | Advanced Neuromodulation Systems, Inc. | Dynamic nerve stimulation in combination with other eating disorder treatment modalities |
| EP2034885A4 (en) | 2006-06-23 | 2010-12-01 | Neurovista Corp | Minimally invasive monitoring systems and methods |
| US8478420B2 (en) * | 2006-07-12 | 2013-07-02 | Cyberonics, Inc. | Implantable medical device charge balance assessment |
| US20080027524A1 (en) * | 2006-07-26 | 2008-01-31 | Maschino Steven E | Multi-electrode assembly for an implantable medical device |
| US20090210026A1 (en) * | 2006-08-17 | 2009-08-20 | Brainsgate Ltd. | Spg stimulation for enhancing neurogenesis and brain metabolism |
| US7660303B2 (en) | 2006-08-22 | 2010-02-09 | Corrigent Systems Ltd. | Point-to-multipoint functionality in a bridged network |
| US8103341B2 (en) * | 2006-08-25 | 2012-01-24 | Cardiac Pacemakers, Inc. | System for abating neural stimulation side effects |
| US8121692B2 (en) * | 2006-08-30 | 2012-02-21 | Cardiac Pacemakers, Inc. | Method and apparatus for neural stimulation with respiratory feedback |
| US8050765B2 (en) | 2006-08-30 | 2011-11-01 | Cardiac Pacemakers, Inc. | Method and apparatus for controlling neural stimulation during disordered breathing |
| US7869867B2 (en) | 2006-10-27 | 2011-01-11 | Cyberonics, Inc. | Implantable neurostimulator with refractory stimulation |
| US8295934B2 (en) | 2006-11-14 | 2012-10-23 | Neurovista Corporation | Systems and methods of reducing artifact in neurological stimulation systems |
| US7697525B2 (en) * | 2006-12-21 | 2010-04-13 | Corrigent Systems Ltd. | Forwarding multicast traffic over link aggregation ports |
| US7706875B2 (en) | 2007-01-25 | 2010-04-27 | Cyberonics, Inc. | Modulation of drug effects by vagus nerve stimulation |
| US20080183097A1 (en) | 2007-01-25 | 2008-07-31 | Leyde Kent W | Methods and Systems for Measuring a Subject's Susceptibility to a Seizure |
| US9898656B2 (en) | 2007-01-25 | 2018-02-20 | Cyberonics, Inc. | Systems and methods for identifying a contra-ictal condition in a subject |
| US7974707B2 (en) * | 2007-01-26 | 2011-07-05 | Cyberonics, Inc. | Electrode assembly with fibers for a medical device |
| US8036736B2 (en) | 2007-03-21 | 2011-10-11 | Neuro Vista Corporation | Implantable systems and methods for identifying a contra-ictal condition in a subject |
| US7904175B2 (en) * | 2007-04-26 | 2011-03-08 | Cyberonics, Inc. | Trans-esophageal vagus nerve stimulation |
| US7869884B2 (en) | 2007-04-26 | 2011-01-11 | Cyberonics, Inc. | Non-surgical device and methods for trans-esophageal vagus nerve stimulation |
| US7962214B2 (en) * | 2007-04-26 | 2011-06-14 | Cyberonics, Inc. | Non-surgical device and methods for trans-esophageal vagus nerve stimulation |
| US7974701B2 (en) | 2007-04-27 | 2011-07-05 | Cyberonics, Inc. | Dosing limitation for an implantable medical device |
| US8781595B2 (en) | 2007-04-30 | 2014-07-15 | Medtronic, Inc. | Chopper mixer telemetry circuit |
| US20080318314A1 (en) * | 2007-06-20 | 2008-12-25 | Valentin Fulga | Production from blood of cells of neural lineage |
| US9788744B2 (en) | 2007-07-27 | 2017-10-17 | Cyberonics, Inc. | Systems for monitoring brain activity and patient advisory device |
| US20090118777A1 (en) * | 2007-08-09 | 2009-05-07 | Kobi Iki | Efferent and afferent splanchnic nerve stimulation |
| US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| EP2207590A1 (en) * | 2007-09-26 | 2010-07-21 | Medtronic, INC. | Therapy program selection |
| US8380314B2 (en) | 2007-09-26 | 2013-02-19 | Medtronic, Inc. | Patient directed therapy control |
| EP2200692B1 (en) * | 2007-09-26 | 2016-11-09 | Medtronic, Inc. | Frequency selective monitoring of physiological signals |
| WO2009051638A1 (en) | 2007-10-16 | 2009-04-23 | Medtronic, Inc. | Therapy control based on a patient movement state |
| US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
| US8942798B2 (en) * | 2007-10-26 | 2015-01-27 | Cyberonics, Inc. | Alternative operation mode for an implantable medical device based upon lead condition |
| US8868203B2 (en) * | 2007-10-26 | 2014-10-21 | Cyberonics, Inc. | Dynamic lead condition detection for an implantable medical device |
| US9089707B2 (en) * | 2008-07-02 | 2015-07-28 | The Board Of Regents, The University Of Texas System | Systems, methods and devices for paired plasticity |
| US20090171168A1 (en) | 2007-12-28 | 2009-07-02 | Leyde Kent W | Systems and Method for Recording Clinical Manifestations of a Seizure |
| US9259591B2 (en) | 2007-12-28 | 2016-02-16 | Cyberonics, Inc. | Housing for an implantable medical device |
| CN101925377A (en) | 2008-01-25 | 2010-12-22 | 麦德托尼克公司 | The detection of Sleep stages |
| US8571643B2 (en) | 2010-09-16 | 2013-10-29 | Flint Hills Scientific, Llc | Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex |
| US11766565B2 (en) | 2008-01-25 | 2023-09-26 | Flint Hills Scientific, L.L.C. | Contingent cardio-protection for epilepsy patients |
| US8337404B2 (en) | 2010-10-01 | 2012-12-25 | Flint Hills Scientific, Llc | Detecting, quantifying, and/or classifying seizures using multimodal data |
| US9579506B2 (en) | 2008-01-25 | 2017-02-28 | Flint Hills Scientific, L.L.C. | Contingent cardio-protection for epilepsy patients |
| US8382667B2 (en) | 2010-10-01 | 2013-02-26 | Flint Hills Scientific, Llc | Detecting, quantifying, and/or classifying seizures using multimodal data |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| WO2009146030A1 (en) * | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
| US8204603B2 (en) * | 2008-04-25 | 2012-06-19 | Cyberonics, Inc. | Blocking exogenous action potentials by an implantable medical device |
| US20090275997A1 (en) * | 2008-05-01 | 2009-11-05 | Michael Allen Faltys | Vagus nerve stimulation electrodes and methods of use |
| US8457747B2 (en) | 2008-10-20 | 2013-06-04 | Cyberonics, Inc. | Neurostimulation with signal duration determined by a cardiac cycle |
| US8417344B2 (en) | 2008-10-24 | 2013-04-09 | Cyberonics, Inc. | Dynamic cranial nerve stimulation based on brain state determination from cardiac data |
| US8478402B2 (en) * | 2008-10-31 | 2013-07-02 | Medtronic, Inc. | Determining intercardiac impedance |
| AU2009316801C1 (en) | 2008-11-18 | 2015-12-24 | Setpoint Medical Corporation | Devices and methods for optimizing electrode placement for anti-inflammatory stimulation |
| US8849390B2 (en) | 2008-12-29 | 2014-09-30 | Cyberonics, Inc. | Processing for multi-channel signals |
| US8588933B2 (en) | 2009-01-09 | 2013-11-19 | Cyberonics, Inc. | Medical lead termination sleeve for implantable medical devices |
| US20100191304A1 (en) | 2009-01-23 | 2010-07-29 | Scott Timothy L | Implantable Medical Device for Providing Chronic Condition Therapy and Acute Condition Therapy Using Vagus Nerve Stimulation |
| US20100268297A1 (en) * | 2009-02-24 | 2010-10-21 | Hans Neisz | Duodenal Stimulation To Induce Satiety |
| US8321030B2 (en) | 2009-04-20 | 2012-11-27 | Advanced Neuromodulation Systems, Inc. | Esophageal activity modulated obesity therapy |
| US8827912B2 (en) | 2009-04-24 | 2014-09-09 | Cyberonics, Inc. | Methods and systems for detecting epileptic events using NNXX, optionally with nonlinear analysis parameters |
| US8239028B2 (en) * | 2009-04-24 | 2012-08-07 | Cyberonics, Inc. | Use of cardiac parameters in methods and systems for treating a chronic medical condition |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| US8886339B2 (en) | 2009-06-09 | 2014-11-11 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
| US8788034B2 (en) | 2011-05-09 | 2014-07-22 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US8340772B2 (en) | 2009-05-08 | 2012-12-25 | Advanced Neuromodulation Systems, Inc. | Brown adipose tissue utilization through neuromodulation |
| US8786624B2 (en) | 2009-06-02 | 2014-07-22 | Cyberonics, Inc. | Processing for multi-channel signals |
| US9770204B2 (en) | 2009-11-11 | 2017-09-26 | Medtronic, Inc. | Deep brain stimulation for sleep and movement disorders |
| WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| EP3636314B1 (en) | 2009-12-23 | 2021-09-08 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
| US9643019B2 (en) | 2010-02-12 | 2017-05-09 | Cyberonics, Inc. | Neurological monitoring and alerts |
| US8478428B2 (en) | 2010-04-23 | 2013-07-02 | Cyberonics, Inc. | Helical electrode for nerve stimulation |
| US8406868B2 (en) | 2010-04-29 | 2013-03-26 | Medtronic, Inc. | Therapy using perturbation and effect of physiological systems |
| US8620425B2 (en) | 2010-04-29 | 2013-12-31 | Medtronic, Inc. | Nerve signal differentiation in cardiac therapy |
| US8639327B2 (en) | 2010-04-29 | 2014-01-28 | Medtronic, Inc. | Nerve signal differentiation in cardiac therapy |
| US8562536B2 (en) | 2010-04-29 | 2013-10-22 | Flint Hills Scientific, Llc | Algorithm for detecting a seizure from cardiac data |
| US8831732B2 (en) | 2010-04-29 | 2014-09-09 | Cyberonics, Inc. | Method, apparatus and system for validating and quantifying cardiac beat data quality |
| US8649871B2 (en) | 2010-04-29 | 2014-02-11 | Cyberonics, Inc. | Validity test adaptive constraint modification for cardiac data used for detection of state changes |
| US8755889B2 (en) | 2010-04-30 | 2014-06-17 | Medtronic, Inc. | Method and apparatus to enhance therapy during stimulation of vagus nerve |
| US10086202B2 (en) * | 2010-05-11 | 2018-10-02 | Cardiac Pacemakers, Inc. | Patient control of therapy suspension |
| EP2569049B1 (en) * | 2010-05-11 | 2018-08-29 | Cardiac Pacemakers, Inc. | Implantable medical device with means for automatically restoring an interrupted therapy |
| US8788045B2 (en) | 2010-06-08 | 2014-07-22 | Bluewind Medical Ltd. | Tibial nerve stimulation |
| US8679009B2 (en) | 2010-06-15 | 2014-03-25 | Flint Hills Scientific, Llc | Systems approach to comorbidity assessment |
| US8641646B2 (en) | 2010-07-30 | 2014-02-04 | Cyberonics, Inc. | Seizure detection using coordinate data |
| US8562524B2 (en) | 2011-03-04 | 2013-10-22 | Flint Hills Scientific, Llc | Detecting, assessing and managing a risk of death in epilepsy |
| US8562523B2 (en) | 2011-03-04 | 2013-10-22 | Flint Hills Scientific, Llc | Detecting, assessing and managing extreme epileptic events |
| US8684921B2 (en) | 2010-10-01 | 2014-04-01 | Flint Hills Scientific Llc | Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis |
| US9457186B2 (en) | 2010-11-15 | 2016-10-04 | Bluewind Medical Ltd. | Bilateral feedback |
| US9186504B2 (en) | 2010-11-15 | 2015-11-17 | Rainbow Medical Ltd | Sleep apnea treatment |
| US8706223B2 (en) | 2011-01-19 | 2014-04-22 | Medtronic, Inc. | Preventative vagal stimulation |
| US8781583B2 (en) | 2011-01-19 | 2014-07-15 | Medtronic, Inc. | Vagal stimulation |
| US8725259B2 (en) | 2011-01-19 | 2014-05-13 | Medtronic, Inc. | Vagal stimulation |
| US8781582B2 (en) | 2011-01-19 | 2014-07-15 | Medtronic, Inc. | Vagal stimulation |
| US8718763B2 (en) | 2011-01-19 | 2014-05-06 | Medtronic, Inc. | Vagal stimulation |
| US9504390B2 (en) | 2011-03-04 | 2016-11-29 | Globalfoundries Inc. | Detecting, assessing and managing a risk of death in epilepsy |
| US9498162B2 (en) | 2011-04-25 | 2016-11-22 | Cyberonics, Inc. | Identifying seizures using heart data from two or more windows |
| US9402550B2 (en) | 2011-04-29 | 2016-08-02 | Cybertronics, Inc. | Dynamic heart rate threshold for neurological event detection |
| US9026214B2 (en) | 2011-06-23 | 2015-05-05 | Cardiac Pacemakers, Inc. | Systems and methods for avoiding aspiration during autonomic modulation therapy |
| US9549677B2 (en) | 2011-10-14 | 2017-01-24 | Flint Hills Scientific, L.L.C. | Seizure detection methods, apparatus, and systems using a wavelet transform maximum modulus algorithm |
| WO2013111137A2 (en) | 2012-01-26 | 2013-08-01 | Rainbow Medical Ltd. | Wireless neurqstimulatqrs |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| US10448839B2 (en) | 2012-04-23 | 2019-10-22 | Livanova Usa, Inc. | Methods, systems and apparatuses for detecting increased risk of sudden death |
| WO2014087337A1 (en) | 2012-12-06 | 2014-06-12 | Bluewind Medical Ltd. | Delivery of implantable neurostimulators |
| US9435830B2 (en) | 2013-01-18 | 2016-09-06 | Cyberonics, Inc. | Implantable medical device depth estimation |
| US10220211B2 (en) | 2013-01-22 | 2019-03-05 | Livanova Usa, Inc. | Methods and systems to diagnose depression |
| US9056195B2 (en) | 2013-03-15 | 2015-06-16 | Cyberonics, Inc. | Optimization of cranial nerve stimulation to treat seizure disorderse during sleep |
| US9370660B2 (en) | 2013-03-29 | 2016-06-21 | Rainbow Medical Ltd. | Independently-controlled bidirectional nerve stimulation |
| US9675796B2 (en) | 2013-11-10 | 2017-06-13 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
| US9585611B2 (en) | 2014-04-25 | 2017-03-07 | Cyberonics, Inc. | Detecting seizures based on heartbeat data |
| US9302109B2 (en) | 2014-04-25 | 2016-04-05 | Cyberonics, Inc. | Cranial nerve stimulation to treat depression during sleep |
| US10130809B2 (en) | 2014-06-13 | 2018-11-20 | Nervana, LLC | Transcutaneous electrostimulator and methods for electric stimulation |
| US9782584B2 (en) | 2014-06-13 | 2017-10-10 | Nervana, LLC | Transcutaneous electrostimulator and methods for electric stimulation |
| US9924904B2 (en) | 2014-09-02 | 2018-03-27 | Medtronic, Inc. | Power-efficient chopper amplifier |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| US9764146B2 (en) | 2015-01-21 | 2017-09-19 | Bluewind Medical Ltd. | Extracorporeal implant controllers |
| US10004896B2 (en) | 2015-01-21 | 2018-06-26 | Bluewind Medical Ltd. | Anchors and implant devices |
| US9597521B2 (en) | 2015-01-21 | 2017-03-21 | Bluewind Medical Ltd. | Transmitting coils for neurostimulation |
| US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| EP3093043B1 (en) | 2015-05-13 | 2018-11-14 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
| US9782589B2 (en) | 2015-06-10 | 2017-10-10 | Bluewind Medical Ltd. | Implantable electrostimulator for improving blood flow |
| US10105540B2 (en) | 2015-11-09 | 2018-10-23 | Bluewind Medical Ltd. | Optimization of application of current |
| US9713707B2 (en) | 2015-11-12 | 2017-07-25 | Bluewind Medical Ltd. | Inhibition of implant migration |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| EP3405255A4 (en) | 2016-01-20 | 2019-10-16 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
| US10695569B2 (en) | 2016-01-20 | 2020-06-30 | Setpoint Medical Corporation | Control of vagal stimulation |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| US10124178B2 (en) | 2016-11-23 | 2018-11-13 | Bluewind Medical Ltd. | Implant and delivery tool therefor |
| US20180353764A1 (en) | 2017-06-13 | 2018-12-13 | Bluewind Medical Ltd. | Antenna configuration |
| US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
| WO2019064175A2 (en) * | 2017-09-29 | 2019-04-04 | Cochlear Limited | Hearing prosthesis |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| EP4153053A1 (en) | 2020-05-21 | 2023-03-29 | The Feinstein Institutes for Medical Research | Systems and methods for vagus nerve stimulation |
| US11400299B1 (en) | 2021-09-14 | 2022-08-02 | Rainbow Medical Ltd. | Flexible antenna for stimulator |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5834215A (en) * | 1981-08-26 | 1983-02-28 | シャープ株式会社 | Clamping member |
| SU1145360A1 (en) * | 1982-12-20 | 1985-03-15 | Университет дружбы народов им.П.Лумумбы | Process for simulating bradycardia |
| JPS63291278A (en) * | 1987-05-22 | 1988-11-29 | Seiko Epson Corp | Manufacture of compound floating magnetic head |
| US4791931A (en) * | 1987-08-13 | 1988-12-20 | Pacesetter Infusion, Ltd. | Demand pacemaker using an artificial baroreceptor reflex |
| JPH01229477A (en) * | 1988-03-09 | 1989-09-13 | Hitachi Ltd | Method and device for production of elastic supporter of magnetic head |
| JPH0782630B2 (en) * | 1989-02-28 | 1995-09-06 | 三菱電機株式会社 | Thin film magnetic head device |
| US5154172A (en) * | 1989-11-13 | 1992-10-13 | Cyberonics, Inc. | Constant current sources with programmable voltage source |
| US5111814A (en) * | 1990-07-06 | 1992-05-12 | Thomas Jefferson University | Laryngeal pacemaker |
-
1991
- 1991-06-14 US US07/715,428 patent/US5205285A/en not_active Expired - Lifetime
-
1992
- 1992-06-12 EP EP92914134A patent/EP0588957B1/en not_active Expired - Lifetime
- 1992-06-12 CA CA002110979A patent/CA2110979C/en not_active Expired - Fee Related
- 1992-06-12 WO PCT/US1992/004819 patent/WO1992022348A1/en active IP Right Grant
- 1992-06-12 AU AU22259/92A patent/AU663719B2/en not_active Ceased
- 1992-06-12 DE DE69231468T patent/DE69231468T2/en not_active Expired - Fee Related
- 1992-06-12 JP JP50096593A patent/JP3414396B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5205285A (en) | 1993-04-27 |
| JPH06511164A (en) | 1994-12-15 |
| DE69231468D1 (en) | 2000-10-26 |
| EP0588957A1 (en) | 1994-03-30 |
| WO1992022348A1 (en) | 1992-12-23 |
| DE69231468T2 (en) | 2001-05-03 |
| JP3414396B2 (en) | 2003-06-09 |
| EP0588957B1 (en) | 2000-09-20 |
| EP0588957A4 (en) | 1997-01-15 |
| AU663719B2 (en) | 1995-10-19 |
| AU2225992A (en) | 1993-01-12 |
| CA2110979A1 (en) | 1992-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2110979C (en) | Voice suppression of vagal stimulation | |
| JP3571651B2 (en) | Activation of the cardiac activity algorithm of the neural stimulator | |
| CA2258812C (en) | Method and apparatus for operating therapy system | |
| CA2259155C (en) | Diagnostic testing methods and apparatus for therapy devices | |
| CA2258759C (en) | Respiratory effort detection method and apparatus | |
| US5188104A (en) | Treatment of eating disorders by nerve stimulation | |
| EP0917485B1 (en) | System for treatment of respiratory disorders | |
| EP0914179B1 (en) | Gain control for a periodic signal | |
| EP0080348B2 (en) | Rate adaptive pacer | |
| US20020156507A1 (en) | Pacemaker for bilateral vocal cord autoparalysis | |
| WO2006124481A2 (en) | Implantable medical device with mri and gradient field induced capture detection methods | |
| AU2002309179A1 (en) | Pacemaker for bilateral vocal cord autoparalysis | |
| Fetter et al. | The clinical incidence and significance of myopotential sensing with unipolar pacemakers | |
| EP0616819B1 (en) | Rate-responsive pacemaker | |
| WO1997043003A1 (en) | Implantable medical device with confirmation of patient activation | |
| AU768822B2 (en) | Method and apparatus for operating therapy system | |
| AU1830801A (en) | System for treatment of respiratory disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |